Medpace Is Expanding Decentralized Clinical Trials & Improving Global Trial Capabilities But Is It ENOUGH? 

Medpace Holdings, Inc. recently reported its second-quarter 2025 earnings, revealing both strengths and challenges. Revenue for the quarter was $603.3 million, marking a 14.2% increase year-over-year. The uptick was driven by higher reimbursable activities, particularly in therapeutic areas like metabolic studies where costs are higher than average, alongside a shift in therapeutic focus away from oncology. Despite cancelations being down across the board, contributing to revenue growth, the company’s ending backlog decreased by 1.8% to approximately $2.9 billion. EBITDA during the quarter saw a 16.2% rise to $130.5 million, reflecting a slight improvement in operational efficiency and productivity, although foreign exchange losses impacted margins.